SCHEMBL17015891

SCHEMBL17015891

c1ccc(-c2cc3ccc4c5ccccc5n(-c5cc6ccccc6c6ccccc56)c4c3n2-c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ IL1R1 P14778 1/20 0.36
▸ KMT2A Q03164 3/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ HAO1 Q9UJM8 1/20 0.35
▸ TSHR P16473 2/20 0.34
▸ APP P05067 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.33
▸ HPRT1 P00492 2/20 0.31
▸ BCHE P06276 1/20 0.31
▸ ACHE P22303 1/20 0.31
▸ KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015889 0.89 L3MBTL1 (0.41) L3MBTL1KDM4EATMCYP2C9IL1R1
SCHEMBL17015892 0.87 KDM4E (0.38) L3MBTL1KDM4EATMCYP2C9IL1R1
SCHEMBL17015808 0.86 L3MBTL1 (0.41) L3MBTL1KDM4EATMCYP1A2CYP2C9
SCHEMBL17015897 0.86 L3MBTL1 (0.41) L3MBTL1KDM4EATMIL1R1KMT2A
SCHEMBL17015893 0.86 L3MBTL1 (0.37) L3MBTL1KDM4EATMIL1R1KMT2A
SCHEMBL17015942 0.86 L3MBTL1 (0.50) L3MBTL1KDM4EATMCYP2C9IL1R1
SCHEMBL17015888 0.86 L3MBTL1 (0.39) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17228248 0.86 L3MBTL1 (0.52) L3MBTL1KDM4EATMCYP1A2CYP2C9
SCHEMBL17015883 0.85 L3MBTL1 (0.42) L3MBTL1KDM4EATMCYP2C9IL1R1
SCHEMBL17015890 0.85 L3MBTL1 (0.38) L3MBTL1KDM4EATMCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885KDM4E 1286/4885ATM 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback